Rating Indicators
VERU Stock: Few Reasons To Be Better
Veru Inc. (NASDAQ: VERU) revealed the findings of phase III trials of antiviral medication for patients with severe COVID-19. In clinical studies, the sabizabulin candidate
Veru Inc. (NASDAQ: VERU) revealed the findings of phase III trials of antiviral medication for patients with severe COVID-19. In clinical studies, the sabizabulin candidate
In trading on June 7, shares of biotech business Veru Inc. (NASDAQ: VERU) surged 16.8 percent to $15.85. VERU, which has a market valuation of
Veru Inc. (NASDAQ:VERU) has a beta of 0.61. The stock’s Relative Strength Index (RSI) is 48.51, with weekly volatility at 3.78% and ATR at 0.39.
Veru Inc. (NASDAQ:VERU) Relative Strength Index (RSI) is 55.74, with weekly volatility at 4.79% and ATR at 0.51. The VERU stock’s 52-week price range has
Veru Inc. (NASDAQ:VERU) Relative Strength Index (RSI) is 58.24, with weekly volatility at 4.64% and ATR at 0.52. The VERU stock’s 52-week price range has
Veru Inc. (NASDAQ:VERU) shares traded higher over the last trading session, gaining 1.97% on 05/27/21. The shares fell to a low of $8.46 before closing
Discover high-quality information at your convenience with ‘State Reviewer.’ Our news portal offers valuable insights for free, available in accessible locations such as metro stations, busy intersections, cafes, and business centers. Wherever your day takes you, ‘State Reviewer’ ensures you’re never out of touch with the latest news and updates.
All rights reserved © 2024, Powered by Smart TechOne